Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase II study demonstrating durable remissions and long-term tolerability.

John C. Byrd,Jennifer A. Woyach,Richard R. Furman,Peter Martin,Susan OBrien,Jennifer R. Brown,Deborah M. Stephens,Jacqueline C. Barrientos,Stephen Devereux,Peter Hillmen,John M. Pagel,Ahmed Hamdy,Raquel Izumi,Priti Patel,Min-Hui Wang,Nitin Jain,William G. Wierda

Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase II study demonstrating durable remissions and long-term tolerability.

2020

John C. Byrd
Jennifer A. Woyach
Richard R. Furman
Peter Martin
Susan OBrien
Jennifer R. Brown
Deborah M. Stephens
Jacqueline C. Barrientos
Stephen Devereux
Peter Hillmen
John M. Pagel
Ahmed Hamdy
Raquel Izumi
Priti Patel
Min-Hui Wang
Nitin Jain
William G. Wierda

8024Background: The next-generation Bruton tyrosine kinase inhibitor acalabrutinib was approved in patients (pts) with treatment-naive (TN) and relapsed/refractory chronic lymphocytic leukemia (CLL...

Keywords:

Chronic lymphocytic leukemia
Oncology
therapy naive
Phases of clinical research
Pathology
Internal medicine
Acalabrutinib
Tolerability
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations